智通财经网·2025-08-11 10:17Core Insights - Fosun Pharma (600196.SH) announced a licensing agreement with Expedition for the global development, production, and commercialization of the investigational product XH-S004, excluding mainland China and Hong Kong and Macau [1] - XH-S004 is a small molecule oral DPP-1 inhibitor aimed at reducing inflammation and preventing airway structural damage, with potential indications including non-cystic fibrosis bronchiectasis and chronic obstructive pulmonary disease [1] - Expedition will pay up to $120 million in non-refundable upfront payments and milestone payments based on development and regulatory achievements, along with up to $525 million in sales milestone payments based on annual net sales in the licensed territories [1] Company Strategy - The collaboration is expected to accelerate the clinical development and commercialization of the licensed product globally [1] - The agreement allows Fosun Pharma to maintain rights for the development, production, and commercialization of the product within mainland China and Hong Kong and Macau, thereby expanding its innovative product portfolio internationally [1]